Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an


           Off-Balance Sheet Arrangement of a Registrant.

On October 12, 2021, Osmotica Pharmaceuticals plc (the "Company") issued $55,000,000 of first tranche notes under the previously disclosed Note Purchase Agreement dated October 1, 2021 (the "Note Purchase Agreement"). A portion of the proceeds of the first tranche notes were used to repay in full the $30.7 million outstanding under the Credit Agreement dated as of February 3, 2016 (as amended, restated or amended and restated from time to time) between the Company, CIT Bank, N.A. (as administrative agent and swingline lender) and the other parties thereto (the "Credit Agreement"). The aggregate proceeds to the Company after the repayment of the $30.7 million outstanding under the Credit Agreement were $22.7 million.

The description of the Note Purchase Agreement included in Item 1.01 of the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on October 6, 2021 is incorporated into this Item 2.03 by reference.

Item 3.02 Unregistered Sales of Equity Securities.

On October 12, 2021, the Company issued and allotted 6,148,832 of the Company's ordinary shares, nominal value $0.01 per share (the "Ordinary Shares"), to Athyrium Opportunities IV Acquisition 2 LP ("Athyrium") for a price of $0.01 per share, or an aggregate price of $61,488.32, pursuant to the previously disclosed Share Subscription Agreement between the Company and Athyrium, dated October 1, 2021. The number of shares issued and allotted to Athyrium is equal to $15,000,000 divided by the volume weighted average price per Ordinary Share in the 60 trading days ended October 8, 2021.




 Item 8.01 Other Events.

On October 6, 2021, the Company entered into an Underwriting Agreement (the "Underwriting Agreement") with H.C. Wainwright & Co., LLC (the "Underwriter") relating to an underwritten public offering (the "Public Offering") of 14,000,000 (the "Firm Shares") of the Company's Ordinary Shares, and warrants to purchase 14,000,000 Ordinary Shares (the "Firm Warrants"). In addition, the Company granted the Underwriter a 30-day option to purchase up to an additional 2,100,000 Ordinary Shares and/or warrants to purchase an additional 2,100,000 Ordinary Shares (the "Optional Warrants" and, together with the Firm Warrants, the "Warrants" and, together with the Firm Shares and Firm Warrants, the "Securities") at the public offering price, less the underwriting discounts and commissions. On October 11, 2021, the Underwriter exercised its right to purchase the Optional Warrants. Each Ordinary Share was offered together with one Warrant at a combined public offering price of $2.50 per Ordinary Share and accompanying Warrant, less underwriting discounts and commissions. The Warrants have an exercise price of $3.10, are exercisable immediately, and will expire three and one half years following the date of issuance. The Underwriting Agreement contains customary representations, warranties and covenants of the Company and also provides for customary indemnification by each of the Company and the Underwriter against certain liabilities. The Public Offering was made pursuant to the Company's effective registration statement on Form S-3 (File No. 333-236193), including the prospectus dated February 12, 2020, as supplemented by a prospectus supplement dated October 6, 2021.

The foregoing description of the Underwriting Agreement and the Warrants does not purport to be complete and is subject to and qualified in its entirety by reference to the full text of the Underwriting Agreement and the Form of the Warrant, copies of which are filed as Exhibit 1.1 and 4.1, respectively, hereto and are incorporated herein by reference.

The legal opinion of A&L Goodbody relating to the Securities is filed herewith as Exhibit 5.1.

In connection with the Public Offering, certain information relating to Part II, Item 14 of the above referenced registration statement under the heading "Other Expenses of Issuance and Distribution" is being filed as Exhibit 99.1 to this Current Report on Form 8-K to be incorporated by reference into such registration statement.

Item 9.01 Financial Statements and Exhibits.





(d) Exhibits.



Exhibit No.                                Description

  1.1           Underwriting Agreement, dated October 6, 2021, by and between
              Osmotica Pharmaceuticals plc and H.C. Wainwright & Co., LLC
  4.1           Form of Warrant
  5.1           Opinion of A&L Goodbody, dated October 12, 2021
  23.1          Consent of A&L Goodbody (included in Exhibit 5.1)
  99.1          Information relating to Part II, Item 14 "Other Expenses of Issuance
              and Distribution" of the Registration Statement on Form S-3 (File
              No. 333-236193)
104           Cover Page Interactive Data File (formatted as Inline XBRL)

© Edgar Online, source Glimpses